Transplant News and Research

RSS

Research offers hope to thousands of UK transplant patients

New research could have an "incredible" impact on the numbers of people being saved through the organ donor system, experts claim today. As demand for organ transplants continues to outstrip supply, a team of scientists from the University of Sunderland are hopeful they may have found a way to expand the donor pool.

12 Jul 2010

Mesoblast schedules formal meeting with FDA to discuss proposed Phase 3 clinical trial program

Australian regenerative medicine company, Mesoblast Limited, today announced that based on positive results from its bone marrow transplant clinical trial conducted at the University of Texas MD Anderson Cancer Center, a formal meeting has been scheduled with the United States Food and Drug Administration to discuss a proposed Phase 3 clinical trial program.

12 Jul 2010

Survival rates for people diagnosed with once-deadly cancer increase: Cancer Research UK

People diagnosed with breast, bowel and ovarian cancers and non-Hodgkin's lymphoma are today twice as likely to survive for at least 10 years as those diagnosed in the early 1970s according to new figures1 released by Cancer Research UK.

12 Jul 2010

Musashi 2 protein predicts progression of AML and CML, identify researchers

Researchers at Whitehead Institute and Children's Hospital Boston have identified a protein, called Musashi 2, that is predictive of prognosis in acute myeloid leukemia and chronic myeloid leukemia patients.

9 Jul 2010

Kiadis Pharma receives FDA approval for IND to start pivotal clinical study for ATIR

Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start the pivotal clinical study for its product ATIR™ in the United States. Kiadis Pharma is currently enrolling patients in a multinational, pivotal clinical study at hospitals in Europe and Canada. With the approval of the IND, US hospitals will also participate in this study.

8 Jul 2010

SurModics licenses biodegradable polymer implant technology to Clinuvel

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it has entered into a license agreement with Clinuvel Pharmaceuticals Limited of Melbourne, Australia. Under the agreement, the Company's SurModics Pharmaceuticals unit has licensed certain of its biodegradable polymer implant technology to Clinuvel for the treatment of sun-induced skin disorders. Terms of the agreement were not disclosed.

8 Jul 2010

Perseid Therapeutics achieves second milestone for CTLA4-Ig therapeutics

Maxygen, Inc., a biotechnology company focused on the development of improved protein drugs, today announced that its majority-owned subsidiary, Perseid Therapeutics LLC, achieved a second preclinical milestone under its collaboration with Astellas Pharma Inc. to co-develop and commercialize next-generation CTLA4-Ig therapeutics.

7 Jul 2010

FDA approves IMT to improve vision in patients with end-stage AMD

The U.S. Food and Drug Administration today announced it has approved the Implantable Miniature Telescope to improve vision in some patients with end-stage age-related macular degeneration.

7 Jul 2010

Preclinical efficacy data of Sangamo's ZFN based human stem cell therapy for HIV published

Sangamo BioSciences, Inc. announced the publication of data demonstrating the preclinical efficacy of a human stem cell therapy for human immunodeficiency virus (HIV) based on its proprietary zinc finger DNA-binding protein nuclease (ZFN) technology.

6 Jul 2010

First Australian intestinal transplant

Mr. Brendan Cole, 32 became the first recipient of a successful intestinal transplant in Australia. Last Friday he had his intestines and organs removed from his abdomen that followed a 12 hour operation at Austin Health.

4 Jul 2010

Transplanted beta cells protect themselves by adapting to their new homes

For transplanted beta cells, life is tough. Not only are the insulin-producing cells in a stranger's body, tucked into the liver rather than the pancreas, they are a bit short on oxygen and blood, and they are often exposed to raised levels of glucose.

3 Jul 2010

ISHLT issues first international consensus formulation of standardized nomenclature for CAV

Cardiac allograft vasculopathy (CAV), the major limitation to long term survival after heart transplantation, occurs when blood vessels in a transplanted heart progressively narrow and lead to dysfunction of the heart muscle or sudden death. Ascertaining benefit from appropriate treatment for this condition has been hampered in part because of the lack of a standard nomenclature.

2 Jul 2010

Researchers develop first model of hormone-induced human prostate cancer initiation and progression

Progress toward understanding the role of sex hormones in the growth of prostate cancer—the most common cancer in U.S. men—has been hindered by the lack of a suitable laboratory research model. Now researchers say they have developed the first model of hormone-induced human prostate cancer initiation and progression.

2 Jul 2010

Allogeneic stem cell transplant holds promise for treatment-resistant chronic lymphocytic leukemia

Allogeneic (donor-derived) stem cell transplant (alloSCT) may be a promising option for patients with treatment-resistant chronic lymphocytic leukemia (CLL), regardless of the patient's underlying genetic abnormalities, according to the results of a study published online today in Blood, the journal of the American Society of Hematology.

2 Jul 2010

New formula may speed up organ allocation process, improve transplant outcomes

Only a small fraction of transplant centers nationwide are willing to accept and transplant deceased-donor kidneys that they perceive as less than perfect, leading to lengthy, organ-damaging delays as officials use a one-by-one approach to find a willing taker.

2 Jul 2010

Research findings suggest new treatment approach to improve corneal transplants

Although it is already one of medicine's most successful transplant procedures, doctors continue to seek ways to improve corneal transplants. Now, for the first time, a team of German and British researchers have confirmed that failure and rejection of transplanted corneas are more likely in patients whose eyes exhibit abnormal vessel growth, called corneal neovascularization, prior to surgery.

1 Jul 2010

Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

Novartis Pharmaceuticals Corporation announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3, was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET.

1 Jul 2010

Mass. reports on people who buy insurance only when sick; Wash. board considers aiding consumers get 'Plan B' referrals; ACLU sues R.I. over electronic records

The Boston Globe: "The number of people who appear to be gaming the state's health insurance system by purchasing coverage only when they are sick quadrupled from 2006 to 2008, according to a long-awaited report released yesterday from the Massachusetts Division of Insurance. The result is that insured residents of Massachusetts wind up paying more for health care, according to the report. … The report was released as state lawmakers consider proposals to make it harder for consumers to jump in and then dump their health insurance coverage" (Lazar, 6/30).

1 Jul 2010

Gen-Probe's APTIMA Trichomonas assay receives European CE mark

Gen-Probe Incorporated announced today that it has received a European CE mark for its APTIMA® assay for Trichomonas vaginalis, a common parasitic sexually transmitted disease.

1 Jul 2010

Neuralstem announces completion of $10 million registered direct offering

Neuralstem, Inc. (NYSE Amex: CUR) announced that it has completed its previously announced registered direct offering of $10 million of units to institutional investors. The units were priced at $2.80 and consisted of: (i) one share of common stock, and (ii) 3/4 common stock purchase warrant. The warrants have an exercise price of $3.25 and a term of three years. Net proceeds from this offering, after deducting placement agent fees and other offering expenses, total approximately $9.2 million. All of the securities were offered pursuant to an effective shelf registration statement.

1 Jul 2010

Transplant News and Research

Research offers hope to thousands of UK transplant patients

Mesoblast schedules formal meeting with FDA to discuss proposed Phase 3 clinical trial program

Survival rates for people diagnosed with once-deadly cancer increase: Cancer Research UK

Musashi 2 protein predicts progression of AML and CML, identify researchers

Kiadis Pharma receives FDA approval for IND to start pivotal clinical study for ATIR

SurModics licenses biodegradable polymer implant technology to Clinuvel

Perseid Therapeutics achieves second milestone for CTLA4-Ig therapeutics

FDA approves IMT to improve vision in patients with end-stage AMD

Preclinical efficacy data of Sangamo's ZFN based human stem cell therapy for HIV published

First Australian intestinal transplant

Transplanted beta cells protect themselves by adapting to their new homes

ISHLT issues first international consensus formulation of standardized nomenclature for CAV

Researchers develop first model of hormone-induced human prostate cancer initiation and progression

Allogeneic stem cell transplant holds promise for treatment-resistant chronic lymphocytic leukemia

New formula may speed up organ allocation process, improve transplant outcomes

Research findings suggest new treatment approach to improve corneal transplants

Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

Mass. reports on people who buy insurance only when sick; Wash. board considers aiding consumers get 'Plan B' referrals; ACLU sues R.I. over electronic records

Gen-Probe's APTIMA Trichomonas assay receives European CE mark

Neuralstem announces completion of $10 million registered direct offering

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News